Ferring Pharmaceuticals, USA today received approval from the U.S. FDA for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA.
The details can be read here.
No comments:
Post a Comment